Harnessing PDX and PDX 2.0: the next-generation paradigm for precision oncology and translational breakthroughs
Abstract Cancer research has achieved remarkable breakthroughs over the past decades with the aid of patient-derived xenograft (PDX) models. However, the limitations of conventional PDX models in hindering clinical translation have become increasingly apparent. In 2025, the National Institutes of He...
Furkejuvvon:
| Váldodahkkit: | , , , , , , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
BMC
2026-02-01
|
| Ráidu: | Molecular Cancer |
| Fáttát: | |
| Liŋkkat: | https://doi.org/10.1186/s12943-026-02594-w |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|